HALO's Phase III Pancreatic Trial Comparing PEGPH20+Abraxane+Gemcitabine (AG) vs AG Failed (among a | CELG Message Board Posts


Celgene Corporation

  CELG website

CELG   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  226243 of 226566  at  11/4/2019 8:47:35 PM  by

klip

The following message was updated on 11/5/2019 8:50:31 AM.

 In response to msg 226239 by  JBWIN
view thread

Re: HALO's Phase III Pancreatic Trial Comparing PEGPH20+Abraxane+Gemcitabine (AG) vs AG Failed (among around a dozen triplet trials that did not improve OS on top of AG)

 
 "Unfortunately, yet another pancreatic triplet trial was unsuccessful."
 
Still a long way to go but I'm hoping this triplet delivers improved efficacy:
 
  • Starpharma advances a new internal DEP® candidate, DEP® gemcitabine, into development
  • DEP® gemcitabine demonstrated significantly enhanced anti-tumour activity compared with Gemzar® (gemcitabine), both alone and in combination with Nab‑paclitaxel (Abraxane®), in a human pancreatic cancer model
  • Gemzar® (gemcitabine), used alone or in combination with Abraxane®, is the current standard of care therapy for pancreatic cancer
  • A patent has been filed for Starpharma’s proprietary DEP® gemcitabine, providing coverage to 2040

Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced results for its next internal development candidate, DEP® gemcitabine.

Starpharma’s proprietary DEP® gemcitabine demonstrated significantly enhanced anti‑tumour activity compared with Gemzar® (gemcitabine), both alone and in combination with Nab-paclitaxel (Abraxane®) in a preclinical human pancreatic cancer model. This data has formed the basis of a new patent application, which will provide coverage over DEP® gemcitabine to 2040. DEP® gemcitabine is one of several internal DEP® candidates under preclinical development by Starpharma.

DEP® gemcitabine is a DEP® version of Lilly’s Gemzar® (gemcitabine) - a well-established anti-cancer drug, which had peak sales of US$1.7 billion. Gemzar® (gemcitabine) is one of the leading chemotherapeutic drugs used to treat pancreatic cancer. It can be administered as a monotherapy or in combination with other therapies such as Abraxane®.

DEP® gemcitabine demonstrated significantly improved anti-tumour activity, compared to Gemzar®, the standard form of gemcitabine, in the human pancreatic cancer xenograft model (p<0.0001). When used in combination with Abraxane®, DEP® gemcitabine significantly outperformed a combination of Gemzar® (gemcitabine) and Abraxane (p<0.005).

About Starpharma’s DEP® platform

Starpharma’s internal pipeline includes a number of pre-clinical DEP® candidates, including DEP® gemcitabine, as well as three clinical stage assets - DEP® docetaxel, DEP® cabazitaxel and DEP® irinotecan. A fourth DEP® drug, DEP® AZD0466 (AstraZeneca’s Bcl2/xL DEP® program), is expected to enter the clinic later this year.

 
 
 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 0  
   Views: 220 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
226566 OT: Starpharma klip 0 4/15/2020 10:51:13 AM


Financial Market Data provided by
.
Loading...